RELX Investor update
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Great. Thank you, everybody. Good afternoon, and for some, good morning. Welcome. I am Paul Sullivan, Head of Investor Relations at RELX, and it is a pleasure to welcome you to our STM Investor Seminar today, and also introduce the CEO of Elsevier, Kumsal Bayazit.
Kumsal. Thank you, Paul. Good afternoon, and good morning to those joining us from the U.S.
Welcome to the STM Investor Seminar. Thank you very much for joining us today. I am Kumsal Bayazit, CEO of Elsevier, the STM division of RELX. I joined RELX in 2004 and have been the CEO of Elsevier for the last eight years. Before that, I held operational and strategic roles in all parts of RELX, in Risk, in Legal, in Exhibitions, as well as at RELX Corporate as Chief Strategy Officer and Chair of the RELX Technology Forum. It has been four years since we last did a deep dive on Elsevier. My team and I are really looking forward to sharing with you the progress we have made since then, as well as the significant opportunity that we see ahead. I will start with an overview of the business and our strategy.
Gemma Hersh will then cover Primary Research. I will come back to cover our decision support tools, and two of our product leaders, Max Khan and Paul Crockett, will bring these to life with product demos. We will then hear from our Chief Technology Officer, Jill Luber, and I will close with some concluding remarks and move to Q&A. Let me start by putting Elsevier in context. In H1 2026, STM represented 28% of RELX revenue and 30% of adjusted operating profit. That equates to annualized revenue of roughly $4 billion or GBP 3 billion, and adjusted operating profit of over GBP 1 billion. We are a very global business with customers in more than 170 countries and territories.
Little over 40% of our revenue comes from North America, a little over 20% from Europe, and just over a third from the rest of the world, which gives us broad exposure to research and healthcare spend around the globe. Almost 80% of revenue is subscription-based, primarily under multi-year contracts, and the rest is transactional, much of it recurring in nature. The large subscription base of the business gives us stability. It also means the positive impact of increasing volumes or new higher value products comes through gradually in our results. A little over half of STM's revenue is in Primary Research. Here, we offer article publishing, research, and analytics platforms. Decision support tools, which we also refer to as databases, tools, and electronic reference, is around 40% of revenues. What we do here is help our customers with evidence-based decisions and tasks through multiple offerings.
The two parts of the business reinforce each other. Primary research gives us the content, the credibility, the domain expertise, and the expert community on which our decision support tools are built. Our decision support tools increase value for our customers by combining that trusted content and curated data with advanced analytics and evolving technologies such as artificial intelligence. We operate in large global segments with attractive structural long-term growth drivers. R&D spend is critical for nations and corporations to drive innovation, economic growth, and solve societal issues such as finding cures for diseases or climate change. This is why, in real terms, global R&D spend has consistently grown at an annualized rate of 5% over decades. In nominal terms, the growth is, of course, higher. This growth trend has been secular and has held through economic cycles, geopolitical tensions, political, and policy changes.
In any given year, of course, there can be ups and downs in spending in any one country or institution or discipline, given budget pressures or short-term fluctuations. Fundamentally, over the long term, global R&D spend continues to grow. This is one of the reasons number of researchers also consistently grows at about 5% per year. I could have shown you this data for 50 years, and you would have seen the same trend, and we expect this growth to continue for many decades to come. Technology advancements have always improved research productivity. It's another driver of growth, and generative AI is having a similar impact.
These drivers, R&D spend, number of researchers, and improving researcher productivity lead to more research, more discoveries, more information and content, higher number of submitted and published articles, and greater demand for more evidence-based decision support tools to understand, build, and apply on knowledge. Looking at health, you can see very similar trends, with global health expenditure growing at 3% a year plus inflation. Number of physicians and nurses has also been consistently growing globally. We serve a large global customer base. We work with over 10,000 academic and government institutions, including virtually all leading research organizations worldwide. We do extensive work with millions of researchers who interact with our tools each year. Our teams have deep connections with research leaders and leading researchers in their fields. We also serve over 2,000 R&D-intensive corporations and work with leading companies in life sciences and biopharma, engineering and technology, chemistry, and energy.
In health, we have solutions for most stakeholders in the health ecosystem, from medical and nursing schools to healthcare providers such as hospitals. No single customer accounts for more than roughly 1% of our revenue. In every segment, our objective is to be a trusted partner and to help customers improve their outcomes so they can, in turn, advance science and healthcare. Our relationships are long-term and deeply embedded in how our customers work, which is a strong foundation for our decision support tools. We have three main strategic priorities. First, we expand customer value in primary research. We continue to deliver industry-leading research quality, article volume, and user experience on leading technology platforms at a lower effective price. Technology advancements such as AI enable significant improvements in the author, editor, and peer reviewer experience and outcomes throughout the whole editorial process.
Second, our decision support tools continue to deliver higher customer value. By combining our deep domain expertise, leading evidence-based scientific content, advanced analytics, and evolving technology, we deliver innovative products that improve customer outcomes in existing and new use cases. You will see examples of that with LeapSpace and Sherpath today. Third, our global modular data and technology platform enables us to build segment-leading products more efficiently. We have always operated with a technology-agnostic approach so that we choose the right tools for each use case as technology evolves. A current example of that is our multi-model AI orchestration layer, so we can optimize for quality, latency, and cost. We also leverage our technology platform internally to accelerate our speed and agility and to drive efficiencies. That is what allows us to innovate at pace and manage cost growth below revenue growth. These priorities reinforce each other.
At our last seminar, I spoke about how we evolved the business towards higher value, high-growth decision support tools, which had improved our revenue growth from 2% to 4%. Since then, we have continued to deliver on that improving long-term trajectory, and we are currently at 6% growth. Equally importantly, during this time period, our customer metrics, including net promoter scores for products and buyers, and customer satisfaction, have been on an improving trajectory. Employee engagement metrics have also improved. Let me talk you through the drivers of our improving revenue growth in a bit more detail. Four years ago, we said that primary research had been growing in the low single digits. Since then, we have delivered increasing growth in submissions, high-quality published articles with an expanding journal portfolio, and improved author, editor, and peer reviewer experience.
That volume growth has started to come through gradually in revenue growth, and we are now growing in mid-single digits in primary research. For decision support tools, at our last seminar, we said revenues were growing in mid to high single digits. As we add more customer value with increasing pace of product innovation, we are now delivering strong growth in the segment. Our objective is to continue on our improving long-term growth trajectory by delivering gradual improvements in both primary research and decision support over the long term. Our objective is also to continue to manage profit growth ahead of revenue growth through process innovation. I hope that this gives you a good overview, STM. I am now going to hand over to Gemma for a deep dive on primary research.
Thank you, Kumsal Bayazit. Hello, everybody. I am Gemma Hersh, Senior Vice President, Primary Research at Elsevier. I have been with Elsevier for over a decade, and I have held a variety of strategic and commercial roles. Today, I will cover what is it that we do in primary research, the value we create for the authors, reviewers, editors, and readers we serve, the opportunity in front of us, and what we are doing to capture it. At the heart of what we do in primary research is supporting researchers and their discoveries. Researchers get funding based on their research proposals from governments, funders, and corporations. They conduct the research, at the end of which they have findings. They codify these findings in an article and look for the right journal in which to share them.
Publishing plays a critical role in how researchers share their contribution with the scientific community and build their reputation and careers. Published articles also enable other researchers to build on this knowledge. We enable that process by helping researchers verify and share their findings. The process starts with the researcher submitting their article to the journal they'd like to be published in. All submitted papers are first assessed by one of the editors of the journal. These editors are recognized experts in the field. Some work as full-time employees, others work part-time alongside roles within academic or research institutions. In total, we work with over 37,000 editors, supported by around 105,000 editorial board members. We have publishing teams who constantly recruit leading experts in their fields as editors and editorial board members. For example, over the past 12 months, we recruited approximately 8,000 new editors and 12,000 editorial board members.
Around 70% of submitted articles do not progress beyond that first assessment, called the editorial review, either because they're not the right fit for the journal or because the science is not yet sound. Papers that progress go to the second assessment, called peer review. This means editors send the article to at least two reviewers who are experts in the specific field. In total, we work with more than 1.9 million reviewers per year. During the peer review process, the author will respond to questions, improve the paper, and sometimes conduct additional work. Peer review pressure tests research findings. Expert peers scrutinize the methods, challenge the conclusions. Their feedback improves papers, sharpens arguments, and highlights gaps so the published record is stronger.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
13 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
